0000000001156986

AUTHOR

Hans Deckmyn

0000-0003-3952-5501

showing 2 related works from this author

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

2020

Recently, we showed that ADAMTS13 circulates in an open conformation during the acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP). Although the cause of this conformational change remains elusive, ADAMTS13 is primarily closed in iTTP patients in remission with ADAMTS13 activity >50% and undetectable anti-ADAMTS13 autoantibodies, as well as after rituximab treatment, suggesting a role for anti-ADAMTS13 autoantibodies. Therefore, immunoglobulin G from 18 acute iTTP patients was purified and added to closed ADAMTS13 in healthy donor plasma. This resulted in open ADAMTS13 in 14 of 18 (78%) samples, proving that anti-ADAMTS13 autoantibodies can induce an open ADAMTS13 con…

Male0301 basic medicine[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematologymedicine.medical_specialtySettore MED/09 - Medicina InternaProtein ConformationImmunologyThrombotic thrombocytopenic purpuraADAMTS13 ProteinBiochemistryImmunoglobulin G03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinehemic and lymphatic diseasesmedicineHumansAutoantibodiesSubclinical infectionPurpura Thrombocytopenic IdiopathicHematology[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybiologybusiness.industryAutoantibody[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyCell BiologyHematologyMiddle Agedmedicine.diseaseADAMTS133. Good health030104 developmental biologyImmunologybiology.proteinFemaleRituximabRituximabbusinessBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies030215 immunologymedicine.drug
researchProduct

Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC

2020

Background: Careful assessment of bleeding history is the first step in the evaluation of patients with mild/moderate bleeding disorders, and the use of a bleeding assessment tool (BAT) is strongly encouraged. Although a few studies have assessed the utility of the ISTH-BAT in patients with inherited platelet function disorders (IPFD) none of them was sufficiently large to draw conclusions and/or included appropriate control groups. Objectives: The aim of the present study was to test the utility of the ISTH-BAT in a large cohort of patients with a well-defined diagnosis of inherited platelets disorder in comparison with two parallel cohorts, one of patients with type-1 von Willebrand disea…

bleeding assessment toolSYMPTOMSMedicina Clínica030204 cardiovascular system & hematologyBLEEDING DISORDERS0302 clinical medicinePlateletINHERITED PLATELET DISORDERSUTILITYRISKbleeding disordersCommunicationbleeding assessment tool; bleeding diathesis; bleeding disorders; inherited platelet disorders; plateletsbleeding diathesisHematologyPLATELETSvon Willebrand DiseasesplateletsBLEEDING DIATHESISLife Sciences & BiomedicineVON-WILLEBRAND-DISEASEmedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDPlatelet Function TestsPlatelet disorderQUESTIONNAIREinherited platelet disorderHemorrhageDIAGNOSIS03 medical and health sciencesInternal medicineSCOREmedicineVon Willebrand diseaseHumansHematologíaIn patientbleeding disorderBLEEDING ASSESSMENT TOOLScience & Technologybleeding diathesibusiness.industrySettore MED/09 - MEDICINA INTERNAMILDmedicine.diseaseLarge cohortBleeding diathesisPeripheral Vascular Diseaseinherited platelet disordersCardiovascular System & CardiologyBlood Platelet Disordersbusiness
researchProduct